Skip to main content
Top
Published in: International Urology and Nephrology 5/2012

01-10-2012 | Urology – Original Paper

Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients

Authors: Stefano C. M. Picozzi, Cristian Ricci, Maddalena Gaeta, Stefano Casellato, Giorgio Bozzini, Dario Ratti, Luca Carmignani

Published in: International Urology and Nephrology | Issue 5/2012

Login to get access

Abstract

Purpose

It is not unusual to encounter the clinical scenario of a male patient undergoing endoscopic treatment for bladder cancer (TURBT) who also needs transurethral resection of prostate (TURP). The aims of this meta-analysis were to understand whether it is oncologically safe or advantageous to combine the two procedures in terms of subsequent overall recurrences with particular interest to that in the prostatic fossa and to understand whether some characteristics of the bladder tumors can influence the recurrence rate.

Methods

A bibliographic search covering the period from January 1950 to December 2011 was conducted in PubMed, MEDLINE and EMBASE. Meta-analysis approach was applied comparing prostatic fossa recurrences and total recurrences in simultaneous TURBT and TURP and control. Also, prostatic fossa recurrences and tumors’ grading and multifocality in patients treated with simultaneous TURBT and TURP were analyzed. To investigate to what extent observational time influenced relapses/recurrence, a random effect meta-regression logistic model–based approach was applied. All statistical evaluations were performed using SAS version 9.2 and by RevMan 5.0. An α level of 0.05 was considered as statistically significant.

Results

Overall, there were 1,234 participants in the eight studies considered. The study group consists of 634 patients and the control group 600. Mean age was 67.88 and 61.64 years, respectively, in the study and control groups. In the study group, on a total of 634 patients, 65 recurrences in the prostatic fossa appear. In the control group, on a total of 600 patients, 58 recurrences in the prostatic fossa occurred. Data do not show a statistically significant difference in recurrence in the prostatic fossa between patients treated simultaneously with TURB and TURP and the control group. Meta-analysis does not show a statistically significant difference in recurrence in the prostatic fossa with the increased grading of the neoplasms. But there is a statistically significant increased recurrence in patients with multifocal tumors. There is a statistically significant reduction in recurrence between patients treated simultaneously with TURB and TURP and the control group, but there is no reduction in the recurrence rate in the time.

Conclusions

This meta-analysis emphasized that the two operations could be performed during the same session without any negative oncologic results. The resolution during the same session of bladder outlet obstruction will improve the patients’ quality of life and performing the procedures in the same session sparing the patients from a further anesthesiological maneuvers and the need for a further hospitalization for the surgical resolution of the prostatic obstruction.
Literature
1.
go back to reference Ploeg M, Aben KKH, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293PubMedCrossRef Ploeg M, Aben KKH, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293PubMedCrossRef
2.
go back to reference Cancer Facts and Figures 2006. American Cancer Society 2006, Atlanta Cancer Facts and Figures 2006. American Cancer Society 2006, Atlanta
3.
go back to reference Greene LF, Yalowitz PA (1972) The advisability of concomitant transurethral excision of vesical neoplasm and prostatic hyperplasia. J Urol 107:445–447PubMed Greene LF, Yalowitz PA (1972) The advisability of concomitant transurethral excision of vesical neoplasm and prostatic hyperplasia. J Urol 107:445–447PubMed
4.
go back to reference Ham WS, Kim WT, Jeon HJ, Lee DH, Choi YD (2009) Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J Urol 181:1594–1599PubMedCrossRef Ham WS, Kim WT, Jeon HJ, Lee DH, Choi YD (2009) Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J Urol 181:1594–1599PubMedCrossRef
5.
go back to reference Jaidane M, Bouicha T, Slama A et al (2010) Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study. Urology 75:1392–1395PubMedCrossRef Jaidane M, Bouicha T, Slama A et al (2010) Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study. Urology 75:1392–1395PubMedCrossRef
6.
go back to reference Laor E, Grabstald H, Whitmore WF (1981) The influence of simultaneous resection of bladder tumors and prostate on the occurrence of prostatic urethral tumors. J Urol 126:171–175PubMed Laor E, Grabstald H, Whitmore WF (1981) The influence of simultaneous resection of bladder tumors and prostate on the occurrence of prostatic urethral tumors. J Urol 126:171–175PubMed
7.
go back to reference Singh V, Sinha RJ, Sankhwar SN (2009) Outcome of simultaneous transurethral resection of bladder tumor and transurethral resection of the prostate in comparison with the procedures in two separate sittings in patients with bladder tumor and urodynamically proven bladder outflow obstruction. J Endourol 23:2007–2011PubMedCrossRef Singh V, Sinha RJ, Sankhwar SN (2009) Outcome of simultaneous transurethral resection of bladder tumor and transurethral resection of the prostate in comparison with the procedures in two separate sittings in patients with bladder tumor and urodynamically proven bladder outflow obstruction. J Endourol 23:2007–2011PubMedCrossRef
8.
go back to reference Tsivian A, Shtricker A, Sidi AA (2003) Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J Urol 170:2241–2243PubMedCrossRef Tsivian A, Shtricker A, Sidi AA (2003) Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J Urol 170:2241–2243PubMedCrossRef
9.
go back to reference Ugurlu O, Gonulalan U, Adsan O, Kosan M, Oztekin V, Cetinkaya M (2007) Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results. Urology 70:55–59PubMedCrossRef Ugurlu O, Gonulalan U, Adsan O, Kosan M, Oztekin V, Cetinkaya M (2007) Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results. Urology 70:55–59PubMedCrossRef
10.
go back to reference Vicente J, Chéchile G, Pons R, Méndez G (1988) Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate. Eur Urol 15:40–42PubMed Vicente J, Chéchile G, Pons R, Méndez G (1988) Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate. Eur Urol 15:40–42PubMed
11.
12.
go back to reference Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457PubMedCrossRef Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457PubMedCrossRef
13.
go back to reference Lindsey J (1993) On the use of correction for overdispersion. Appl Stat 48:553–561 Lindsey J (1993) On the use of correction for overdispersion. Appl Stat 48:553–561
14.
go back to reference Albarran J, Imbert L (1903) Les tumeurs du rein. Masson, Paris, pp 452–459 Albarran J, Imbert L (1903) Les tumeurs du rein. Masson, Paris, pp 452–459
15.
go back to reference Kouriefs C, Loizides S, Mufti G (2008) Simultaneous transurethral resection of bladder tumour and prostate: is it safe? Urol Int 81:125–128PubMedCrossRef Kouriefs C, Loizides S, Mufti G (2008) Simultaneous transurethral resection of bladder tumour and prostate: is it safe? Urol Int 81:125–128PubMedCrossRef
16.
go back to reference Kiefer JH (1953) Bladder tumor recurrence in the urethra: a warning. J Urol 69:652–656PubMed Kiefer JH (1953) Bladder tumor recurrence in the urethra: a warning. J Urol 69:652–656PubMed
17.
go back to reference Hinman F (1956) Recurrence of bladder tumors by surgical implantation. J Urol 75:695–696PubMed Hinman F (1956) Recurrence of bladder tumors by surgical implantation. J Urol 75:695–696PubMed
18.
go back to reference Golomb J, Gorelik U, Keler T, Lindner A (1989) Incidence and pattern of bladder tumor recurrence following combined suprapubic prostatectomy and excision of a bladder tumor. Eur Urol 16:86–88PubMed Golomb J, Gorelik U, Keler T, Lindner A (1989) Incidence and pattern of bladder tumor recurrence following combined suprapubic prostatectomy and excision of a bladder tumor. Eur Urol 16:86–88PubMed
19.
go back to reference Ham WS, Kim WT, Jeon HJ, Lee DH, Choi YD (2009) Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J Urol 181:1594–1599PubMedCrossRef Ham WS, Kim WT, Jeon HJ, Lee DH, Choi YD (2009) Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J Urol 181:1594–1599PubMedCrossRef
20.
go back to reference Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466CrossRef Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466CrossRef
21.
go back to reference Kaasinen E, Rintala E, Hellstrom P, FinnBladder Group et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167–174PubMedCrossRef Kaasinen E, Rintala E, Hellstrom P, FinnBladder Group et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167–174PubMedCrossRef
22.
go back to reference Stenzl A, Cowan NC, De Santis M, European Association of Urology (EAU) (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018PubMedCrossRef Stenzl A, Cowan NC, De Santis M, European Association of Urology (EAU) (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018PubMedCrossRef
23.
go back to reference Pawinski A, Sylvester R, Kurth KH et al (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. J Urol 156:1934–1940PubMedCrossRef Pawinski A, Sylvester R, Kurth KH et al (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. J Urol 156:1934–1940PubMedCrossRef
24.
go back to reference Huncharek M, Geschwind J-F, Witherspoon B et al (2000) Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53:676–680PubMedCrossRef Huncharek M, Geschwind J-F, Witherspoon B et al (2000) Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53:676–680PubMedCrossRef
25.
go back to reference Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21:765–769PubMed Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21:765–769PubMed
Metadata
Title
Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients
Authors
Stefano C. M. Picozzi
Cristian Ricci
Maddalena Gaeta
Stefano Casellato
Giorgio Bozzini
Dario Ratti
Luca Carmignani
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0183-3

Other articles of this Issue 5/2012

International Urology and Nephrology 5/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.